Lupin share price hits 52-week high on launch of overactive bladder drug in US - Mint
Lupin's share price surged over 1% to a 52-week high after USFDA approval for its generic Mirabegron tablets for overactive bladder. Lupin and Zydus are the only companies with approval for both 25 mg and 50 mg strengths, enjoying 6 months exclusivity. Lupin also launched doxorubicin hydrochloride liposome injection in the US.
Reference News
Lupin share price hits 52-week high on launch of overactive bladder drug in US - Mint
Lupin's share price surged over 1% to a 52-week high after USFDA approval for its generic Mirabegron tablets for overactive bladder. Lupin and Zydus are the only companies with approval for both 25 mg and 50 mg strengths, enjoying 6 months exclusivity. Lupin also launched doxorubicin hydrochloride liposome injection in the US.